Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis

Bone

Volumn 67, Issue , 2014, Pages 189-192

  Gatti, Davide ^a   Viapiana, Ombretta ^a   Idolazzi, Luca ^a   Fracassi, Elena ^a   Ionescu, Claudio ^a   Dartizio, Carmela ^a   Troplini, Sonila ^a   Kunnathully, Vidya ^a   Adami, Silvano ^a   Rossini, Maurizio ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Clodronate; DKK 1; Sclerostin; Zoledronate

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; COLLAGEN; DICKKOPF 1 PROTEIN; N PROPEPTIDE OF TYPE 1 COLLAGEN; PLACEBO; SCLEROSTIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; DKK1 PROTEIN, HUMAN; GENETIC MARKER; IMIDAZOLE DERIVATIVE; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ADULT; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETIC MARKER; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; GENETIC MARKERS; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84904904408     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.037     Document Type: Article

References (18)

1. Rossini M., Gatti D., Adami S. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 2013, 93:121-132.
2. Baron R., Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
3. Ott S.M. Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 2005, 90:6741-6743.
4. Gatti D., Viapiana O., Adami S., Idolazzi L., Fracassi E., Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2012, 50:739-742.
5. Gatti D., Viapiana O., Fracassi E., Idolazzi L., Dartizio C., Povino M.R., et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 2012, 27:2259-2263.
6. Rossini M., Braga V., Gatti D., Gerardi D., Zamberlan N., Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone 1999, 24:125-129.
7. Rossini M., Adami S., Viapiana O., Tripi G., Zanotti R., Ortolani R., et al. Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif Tissue Int 2013, 93:249-252.
8. Anastasilakis A.D., Polyzos S.A., Toulis K.A. Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge. Curr Opin Endocrinol Diabetes Obes 2011, 18:383-388.
9. Drake M.T., Srinivasan B., Mödder U., Peterson J.M., McCready L.K., Riggs B.L., et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95:5056-5062.
10. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136:3632-3638.
11. Gasser J.A., Ingold P., Venturiere-Rebmann A., Green J.R. Chronic subcutaneous, but not single intravenous, dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. Paper presented at: American Society for Bone and Mineral Research 28th Annual Meeting; 15-19 September 2006; Philadelphia, Pa. Poster F386;SA386 2006.
12. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. PaTH study investigators, the effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
13. Cosman F., Eriksen E.F., Recknor C., Miller P.D., Guañabens N., Kasperk C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
14. Catalano A., Morabito N., Basile G., Brancatelli S., Cucinotta D., Lasco A. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2013, 98:1911-1915.
15. Anastasilakis A.D., Polyzos S.A., Gkiomisi A., Bisbinas I., Gerou S., Makras P. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 2013, 98:3206-3212.
16. Bone H.G., Chapurlat R., Brandi M.L., Brown J.P., Czerwinski E., Krieg M.A., et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013, 98:4483-4492.
17. Boonen S., Ferrari S., Miller P.D., Eriksen E.F., Sambrook P.N., Compston J., et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012, 27:963-974.
18. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., et al. The effect of 3 versus 6years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.